<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03268811</url>
  </required_header>
  <id_info>
    <org_study_id>SHP633-305</org_study_id>
    <nct_id>NCT03268811</nct_id>
  </id_info>
  <brief_title>A Study in Japanese Children With Short Bowel Syndrome Who Completed SHP633-302</brief_title>
  <official_title>A Prospective, Open-label, Long-term Safety and Efficacy Study of Teduglutide in Japanese Pediatric Subjects With Short Bowel Syndrome Who Completed SHP633-302</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study in Japanese Children with Short Bowel Syndrome Who Completed SHP633-302
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AE)</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Gastrointestinal (GI) Symptoms Reported as an Adverse Event</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment.administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. Events specific with the GI symptoms and reported as AE will be considered for reporting.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Abnormalities in Vital Signs Reported as an Adverse Event</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>Vital signs included systolic and diastolic blood pressure, pulse and body temperature. Clinically significant value defines if the change is clinically relevant or if, during treatment with investigational product, a shift of a parameter is observed from a normal value to an abnormal value, or a further worsening of an already abnormal value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Clinically Significant Lab and Safety Analysis Reported as an Adverse Event</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>Lab and safety analysis included biochemistry, hematology and urinalysis. Clinically significant value defines if the change is clinically relevant or if, during treatment with investigational product, a shift of a parameter is observe d from a normal value to an abnormal value, or a further worsening of an already abnormal value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Significant Change in Urine Output Reported as an Adverse Event</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>Urine output will be recorded in the output diary over a 48-hour period of parenteral support (PS) stability before every clinic visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Significant Change in Stool Output Reported as an Adverse Event</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>Stool output will be recorded in the output diary over a 48-hour period of PS stability before every clinic visit.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Positive Specific or Neutralizing Antibodies to Teduglutide Reported as an Adverse Event</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>Blood samples will be drawn for the analysis of positive/specific antibodies to teduglutide according to the study schedules.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With a Positive Fecal Occult Blood Testing</measure>
    <time_frame>From start of treatment till EOT (up to 24 Weeks)</time_frame>
    <description>Gastrointestinal-specific assessment will be analysed by fecal occult blood testing. Subjects with newly positive fecal occult blood testing results at the pre-treatment visit for which a readily detectable cause cannot be identified (example: anal fissure ) will undergo a colonoscopy prior to receiving teduglutide.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 28 in Z-Score Body Weight</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 28 in Z-Score Height</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 28 in Z-Score Head Circumference</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Week 28 in Z-Score Body Mass Index (BMI)</measure>
    <time_frame>From start of treatment up to follow up (Week 28)</time_frame>
    <description>The Z-score indicates the number of standard deviations away from the mean.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction in Parenteral Support (PS) Volume</measure>
    <time_frame>Week 24 or end of treatment [EOT]</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period. PS volume of at least 20 percent (%) will be considered for the analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change in Parenteral Support (PS) Volume at Week 24/End of Treatment [EOT]</measure>
    <time_frame>Week 24/EOT</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change in Parenteral Support (PS) Volume at Week 24/End of Treatment [EOT]</measure>
    <time_frame>Week 24/EOT</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Weaning Off Parenteral Support (PS)</measure>
    <time_frame>Week 24/EOT</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period. Weaning will be calculated as per the protocol mentioned algorithm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Days per Week of Parenteral Support (PS)</measure>
    <time_frame>Week 24/EOT</time_frame>
    <description>PS (parenteral nutrition or intravenous fluids) will be considered for managing nutritional support in terms of volume and calories during the treatment period. Change in PS was calculated in days per week.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Short Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>Teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care (SOC) treatment +/- teduglutide. Depending on teduglutide treatment eligibility, subjects may receive teduglutide 0.05 mg/kg subcutaneous once daily for 24-week intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Teduglutide 0.05 mg/kg SC injection once daily.</description>
    <arm_group_label>Teduglutide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject provides written informed consent (subject, parent or legal guardian and, as
             appropriate, informed assent) to participate in the study before completing any
             study-related procedures.

          -  When applicable, informed assent (as deemed appropriate by the Institutional Review
             Board [IRB]) by the subject prior to any study-related procedures.

          -  Subject completed Study SHP633-302 (NCT02980666).

          -  Subject (and/or parent/legally authorized representative) understands and is willing
             and able to fully adhere to study requirements as defined in this protocol.

        Exclusion Criteria:

        There are no exclusion criteria for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shire Physician</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shire Contact</last_name>
    <phone>1 866-842-5335</phone>
    <email>ClinicalTransparency@shire.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyushu University Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-ken</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Toshiharu Matsuura</last_name>
      <phone>+819264111151</phone>
      <email>matsuura@pedsurg.med.kyushu-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Toshiharu Matsuura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tsukuba University Hospital</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki-Ken</state>
        <zip>305-8576</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kouji Masumoto</last_name>
      <phone>+181298533900</phone>
      <email>kmasu@md.tsukuba.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Kouji Masumoto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kagoshima University Hospital</name>
      <address>
        <city>Kagoshima</city>
        <state>Kagoshima-Ken</state>
        <zip>890-8520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuru Kaji</last_name>
      <phone>+81992755111</phone>
      <email>tatu@m2.kufm.kagoshima-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Tatsuru Kaji</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tohoku University Hospital</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi-Ken</state>
        <zip>980-8574</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Motoshi Wada</last_name>
      <phone>+81227177000</phone>
    </contact>
    <investigator>
      <last_name>Motoshi Wada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Showa University</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo-To</state>
        <zip>142-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Masahiro Chiba</last_name>
      <phone>+81337848000</phone>
    </contact>
    <investigator>
      <last_name>Masahiro Chiba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2017</study_first_submitted>
  <study_first_submitted_qc>August 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Short Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

